Analyst upgrades over the last week provide an additional tailwind to the LLY stock price today forecast. With consensus targets now approaching $800, momentum traders have clear room for potential upside continuation. Blue-chip companies gained 485.60 points or 1.14%, the broader market index rose 1.12%, while the NASDAQ stocks increased 1.46%. These rebounds come during a volatile week following a period of consecutive declines. Guidance for diabetes drug Mounjaro is $3.5 billion, while weight loss drug Zepbound is expected to bring in $1.9 billion for the quarter. From a valuation lens, today’s LLY stock price forecast ties in with forward P/E ratios above the sector average, justified by double-digit revenue growth potential. Shares currently trade around $758, maintaining upward pressure despite broader market volatility.